Hirose, A; Ono, M; Saibara, T; Nozaki, Y; Masuda, K; Yoshioka, A; ... Oben, JA; + view all Hirose, A; Ono, M; Saibara, T; Nozaki, Y; Masuda, K; Yoshioka, A; Takahashi, M; Akisawa, N; Iwasaki, S; Onishi, S; Oben, JA; - view fewer (2007) Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology , 45 (6) 1375 - 1381. 10.1002/hep.21638.
Full text not available from this repository.
Nonalcoholic steatohepatitis (NASH) is now the most frequent cause of chronic liver impairment in developed countries and is a suggested causative factor in the development of cryptogenic cirrhosis and hepatocellular carcinoma. At present there is no effective and accepted therapy for NASH. The renin-angiotensin system is involved in hepatic fibrosis through activation of hepatic stellate cells, major fibrogenic cells in the liver. Hepatic stellate cells are activated by liver injury to express excessive matrix proteins and profibrogenic cytokines such as transforming growth factor-beta 1. Medicines that inhibit this pathway may be of therapeutic potential in NASH. Using a methionine-choline-deficient rat model of NASH, we studied the potential utility of an angiotensin II type 1 receptor blocker (ARB), olmesartan, on biochemical, histologic, and antioxidant measures of disease activity. ARB significantly attenuated increases in aspartate aminotransferase, activation of hepatic stellate cells, oxidative stress, expression of transforming growth factor-beta 1, expression of collagen genes, and liver fibrosis. Conclusion: Our observations strongly suggest a potential preventive role for ARB in the progression of nonalcoholic steatohepatitis. Copyright © 2007 by the American Association for the Study of Liver Diseases.
|Title:||Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis|
Archive Staff Only: edit this record